Patents by Inventor Daisuke Wakamatsu
Daisuke Wakamatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10676438Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: June 9, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20200157050Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
-
Patent number: 10570093Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: February 25, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Patent number: 10519105Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: GrantFiled: April 21, 2017Date of Patent: December 31, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190135755Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.Type: ApplicationFiled: April 21, 2017Publication date: May 9, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
-
Publication number: 20190127320Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: ApplicationFiled: April 21, 2017Publication date: May 2, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
-
Patent number: 10196358Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 8, 2017Date of Patent: February 5, 2019Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20180346422Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: August 9, 2018Publication date: December 6, 2018Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke WAKAMATSU, Tetsuji SAITO
-
Publication number: 20170334855Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: August 8, 2017Publication date: November 23, 2017Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Patent number: 9809544Abstract: The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 23, 2015Date of Patent: November 7, 2017Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20170217888Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: October 23, 2015Publication date: August 3, 2017Applicant: Ono Pharmaceutical Co., LtdInventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
-
Publication number: 20090226412Abstract: The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.Type: ApplicationFiled: June 23, 2006Publication date: September 10, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.,Inventors: Tetsuya Yasuhiro, Takashi Kitajima, Daisuke Wakamatsu, Wataru Kamoshima
-
Patent number: 6926915Abstract: The present invention provides a method for selective and high-yield separation, concentration, and recovery of desired cells from a blood sample.Type: GrantFiled: March 30, 2000Date of Patent: August 9, 2005Assignee: Netech, Inc.Inventors: Hirofumi Yura, Yoshio Saito, Michihiro Kitagawa, Daisuke Wakamatsu, Akira Ihara
-
Publication number: 20050042354Abstract: It is intended to obtain highly active and fat-soluble antiradicals originating in a natural substance whereby the stability of foods (fat compositions) can be elevated and disorders caused by oxidation in vivo can be prevented simultaneously. Namely (1) an antiradical containing 4-vinyl-2,6-dimethoxyphenol as the active ingredient; (2) an antiradical comprising an extract of crude rapeseed oil containing 4-vinyl-2,6-dimethoxyphenol; (3) a crude rapeseed oil extract containing 4-vinyl-2,6-dimethoxyphenol in a concentrated state characterized by being prepared by treating crude rapeseed oil with an alcohol or an aqueous alcohol or distilling it; and (4) an antiradical containing these three types of crude rapeseed oil extracts.Type: ApplicationFiled: October 9, 2002Publication date: February 24, 2005Inventors: Shigeru Morimura, Kenji Kida, Hiroshi Maeda, Fumi Yasuda, Daisuke Wakamatsu, Jun Tsunehiro, Chiaki Nakai
-
Publication number: 20050032201Abstract: The present invention provides a method for selective and high-yield separation, concentration, and recovery of desired cells from a blood sample.Type: ApplicationFiled: September 9, 2004Publication date: February 10, 2005Applicant: NETECH INC.Inventors: Hirofumi Yura, Yoshio Saito, Michihiro Kitagawa, Daisuke Wakamatsu, Akira Ihara